Timosaponin BII inhibits TGF ‐β mediated epithelial‐mesenchymal transition through Smad‐dependent pathway during pulmonary fibrosis
Phytotherapy Research · 2023
DOI: 10.1002/ptr.7774 ↗At a glance
Journal article in Phytotherapy Research, 2023. Written by Dali Ding and 9 co-authors. Institution: School of Pharmacy, Wannan Medical College, Wuhu, China. Major MEDLINE topics: Pulmonary Fibrosis. Cited 24 times so far (Crossref); 31 references. Funded by: Foundation for Natural Science Foundation of the Higher Education Institutions of Anhui Province, Foundation of the Academic and technical leaders in Wannan Medical College reserve candidates, Key Science and Technology Program of Anhui Province.
Abstract (original language)
Pulmonary fibrosis (PF) is a progressive and fatal interstitial lung disease with limited therapeutic options at present, and epithelial–mesenchymal transition (EMT) is recognized as a major cause of lung fibrosis. Our previous work has confirmed that total extract of Anemarrhena asphodeloides Bunge [Asparagaceae] exerted the effect of anti‐PF. As a main constituent of Anemarrhena asphodeloides Bunge [Asparagaceae], the effect of timosaponin BII (TS BII) on drug‐induced EMT process in PF animals and alveolar epithelial cells remains unknown. In this study, we evaluated the effect of TS BII on bleomycin (BLM)‐induced PF. The results showed that TS BII could restore the structure of lung architecture and MMP‐9/TIMP‐1 balance in fibrotic rat lung and inhibit collagen deposition. Moreover, we found that TS BII could reverse the abnormal expression of TGF‐β1 and EMT‐related marker proteins including E‐cadherin, vimentin, and α‐SMA. Besides, aberrant TGF‐β1 expression and phosphorylation of Smad2 and Smad3 in BLM‐induced animal model and TGF‐β1‐induced cell model were downregulated by TS BII treatment, indicating that EMT in fibrosis was suppressed by inhibition of TGF‐β/Smad pathway both in vivo and in vitro. In summary, our study suggested that TS BII could be a promising candidate for PF treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Pharmacy, Wannan Medical College, Wuhu, China.
- Pharmacy Department, The PLA Navy Anqing Hospital, Anqing, China.
- Institute of Modern Chinese Medicine, Wannan Medical College, Wuhu, China.
- Anhui Provincial Engineering Laboratory for Screening and Re-evaluation of Active Compounds of Herbal Medicines in Southern Anhui, Wannan Medical College, Wuhu, China.
- School of Pharmacy, Anhui College of Traditional Chinese Medicine, Wuhu, China.
ORCID profiles: Xuebin Shen, Sihui Nian
Funding
- Foundation for Natural Science Foundation of the Higher Education Institutions of Anhui Province
- Foundation of the Academic and technical leaders in Wannan Medical College reserve candidates
- Key Science and Technology Program of Anhui Province
- Key Science and Technology Program of Wuhu City
- The University Synergy Innovation Program of Anhui Province
Cite
APA
Ding, D., Shen, X., Yu, L., Zheng, Y., Liu, Y., Wang, W., Liu, L., Zhao, Z., Nian, S., & Liu, L. (2023). Timosaponin BII inhibits TGF ‐β mediated epithelial‐mesenchymal transition through Smad‐dependent pathway during pulmonary fibrosis. Phytotherapy Research. https://doi.org/10.1002/ptr.7774
Vancouver
Ding D, Shen X, Yu L, Zheng Y, Liu Y, Wang W, et al. Timosaponin BII inhibits TGF ‐β mediated epithelial‐mesenchymal transition through Smad‐dependent pathway during pulmonary fibrosis. Phytotherapy Research. 2023. doi:10.1002/ptr.7774
BibTeX
@article{Ding2023,
author = {Ding, Dali and Shen, Xuebin and Yu, Lizhen and Zheng, Yueyue and Liu, Yao and Wang, Wei and Liu, Li and Zhao, Zitong and Nian, Sihui and Liu, Limin},
title = {Timosaponin BII inhibits TGF ‐β mediated epithelial‐mesenchymal transition through Smad‐dependent pathway during pulmonary fibrosis},
journal = {Phytotherapy Research},
year = {2023},
doi = {10.1002/ptr.7774}
}
EUVIMED